Specific	O
depletion	O
of	O
the	O
B-cell	B-cell_line
population	I-cell_line
induced	O
by	O
aberrant	O
expression	O
of	O
human	B-DNA
interferon	I-DNA
regulatory	I-DNA
factor	I-DNA
1	I-DNA
gene	I-DNA
in	O
transgenic	O
mice	O
.	O

Interferons	B-protein
(	O
IFNs	B-protein
)	O
are	O
well	O
known	O
both	O
as	O
antiviral	B-protein
proteins	I-protein
and	O
as	O
potent	O
regulators	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
fact	O
,	O
IFNs	B-protein
inhibit	O
growth	O
of	O
various	O
normal	B-cell_type
and	O
transformed	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O

Previously	O
,	O
a	O
nuclear	B-protein
factor	I-protein
,	O
IRF-1	B-protein
(	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
)	O
,	O
which	O
binds	O
to	O
type	B-DNA
I	I-DNA
IFN	I-DNA
and	O
some	O
IFN-inducible	B-DNA
gene	I-DNA
promoters	I-DNA
,	O
was	O
identified	O
and	O
cloned	O
.	O

Since	O
the	O
IRF-1	B-protein
gene	O
is	O
both	O
virus	O
and	O
IFN	B-protein
inducible	O
,	O
an	O
intriguing	O
issue	O
is	O
raised	O
as	O
to	O
whether	O
the	O
IRF-1	B-DNA
gene	I-DNA
is	O
functioning	O
in	O
IFN	B-protein
-mediated	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
transgenic	O
mice	O
carrying	O
the	O
human	B-DNA
IRF-1	I-DNA
gene	I-DNA
linked	O
to	O
the	O
human	B-DNA
immunoglobulin	I-DNA
heavy-chain	I-DNA
enhancer	I-DNA
.	O

In	O
the	O
transgenic	O
mice	O
,	O
all	O
the	O
lymphoid	O
tissues	O
examined	O
showed	O
a	O
dramatic	O
reduction	O
in	O
the	O
number	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
(	O
B	B-cell_type
cells	I-cell_type
)	O
.	O

Preparation	O
and	O
analysis	O
of	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
from	O
the	O
chimeric	O
mice	O
indicated	O
that	O
the	O
bone	O
marrow	O
is	O
the	O
effective	O
site	O
for	O
specific	O
depletion	O
of	O
the	O
B-cell	B-cell_type
population	I-cell_type
.	O

In	O
fact	O
,	O
transgenic	B-cell_line
bone	I-cell_line
marrow	I-cell_line
cells	I-cell_line
cocultured	O
with	O
a	O
bone	B-cell_line
marrow-derived	I-cell_line
stromal	I-cell_line
cell	I-cell_line
line	I-cell_line
revealed	O
an	O
altered	O
B-cell	B-cell_type
maturation	O
pattern	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

88	NULL
,	NULL
pp	NULL
.	NULL

532-536	NULL
,	NULL
January	NULL
1991	NULL
Immunology	NULL
Specific	NULL
depletion	NULL
of	NULL
the	NULL
B-cell	NULL
population	NULL
induced	NULL
by	NULL
aberrant	NULL
expression	NULL
of	NULL
human	NULL
interferon	NULL
regulatory	NULL
factor	NULL
1	NULL
gene	NULL
in	NULL
transgenic	NULL
mice	NULL
(	NULL
transcription	NULL
factor	NULL
/negative	NULL
growth	NULL
factor	NULL
/cytokines/gene	NULL
regulation	NULL
)	NULL
GEn	NULL
Yamapa*	NULL
,	NULL
MinEtTARO	NULL
OgaAwa	NULL
'	NULL
!	NULL

,	NULL
Krwamy	NULL
Axactt	NULL
,	NULL
Hame	NULL
MIryaAmMoTO®	NULL
,	NULL
NAOKO	NULL
NAKANO®*	NULL
,	NULL
Susumu	NULL
Iron*	NULL
,	NULL
Jun-icH1	NULL
MryazaAx1	NULL
,	NULL
?	NULL

,	NULL
Suin-icH1	NULL
NisHikawa	NULL
?	NULL

,	NULL
Ken-1cH1	NULL
YamamurRA	NULL
#	NULL
,	NULL
anp	NULL
TaADaATsuGU	NULL
TANIGUCHI*	NULL
*Institute	NULL
for	NULL
Molecular	NULL
and	NULL
Cellular	NULL
Biology	NULL
,	NULL
Osaka	NULL
University	NULL
,	NULL
Yamada-oka	NULL
1-3	NULL
,	NULL
Suita-shi	NULL
,	NULL
Osaka	NULL
565	NULL
,	NULL
Japan	NULL
;	NULL
*Institute	NULL
for	NULL
Medical	NULL
Immunology	NULL
,	NULL
Kumamoto	NULL
University	NULL
Medical	NULL
School	NULL
,	NULL
Honjo	NULL
2-2-1	NULL
,	NULL
Kumamoto	NULL
860	NULL
,	NULL
Japan	NULL
;	NULL
and	NULL
*Institute	NULL
for	NULL
Medical	NULL
Genetics	NULL
,	NULL
Kumamoto	NULL
University	NULL
Medical	NULL
School	NULL
,	NULL
Kuonji	NULL
424-1	NULL
,	NULL
Kumamoto	NULL
862	NULL
,	NULL
Japan	NULL
Communicated	NULL
by	NULL
Mark	NULL
Ptashne	NULL
,	NULL
September	NULL
19	NULL
,	NULL
1990	NULL
(	NULL
received	NULL
for	NULL
review	NULL
August	NULL
14	NULL
,	NULL
1990	NULL
)	NULL
ABSTRACT	NULL
Interferons	NULL
(	NULL
IFNs	NULL
)	NULL
are	NULL
well	NULL
known	NULL
both	NULL
as	NULL
antiviral	NULL
proteins	NULL
and	NULL
as	NULL
potent	NULL
regulators	NULL
of	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
IFNs	NULL
inhibit	NULL
growth	NULL
of	NULL
various	NULL
normal	NULL
and	NULL
transformed	NULL
cell	NULL
types	NULL
.	NULL

Previously	NULL
,	NULL
a	NULL
nuclear	NULL
factor	NULL
,	NULL
IRF-1	NULL
(	NULL
interferon	NULL
regulatory	NULL
factor	NULL
1	NULL
)	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
type	NULL
I	NULL
IFN	NULL
and	NULL
some	NULL
IFN-inducible	NULL
gene	NULL
promoters	NULL
,	NULL
was	NULL
identified	NULL
and	NULL
cloned	NULL
.	NULL

Since	NULL
the	NULL
IRF-1	NULL
gene	NULL
is	NULL
both	NULL
virus	NULL
and	NULL
IFN	NULL
inducible	NULL
,	NULL
an	NULL
intriguing	NULL
issue	NULL
is	NULL
raised	NULL
as	NULL
to	NULL
whether	NULL
the	NULL
IRF-1	NULL
gene	NULL
is	NULL
functioning	NULL
in	NULL
IFN-mediated	NULL
regulation	NULL
of	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
generated	NULL
transgenic	NULL
mice	NULL
carrying	NULL
the	NULL
human	NULL
IRF-1	NULL
gene	NULL
linked	NULL
to	NULL
the	NULL
human	NULL
immunoglobulin	NULL
heavy-chain	NULL
enhancer	NULL
.	NULL

In	NULL
the	NULL
transgenic	NULL
mice	NULL
,	NULL
all	NULL
the	NULL
lymphoid	NULL
tissues	NULL
examined	NULL
showed	NULL
a	NULL
dramatic	NULL
reduction	NULL
in	NULL
the	NULL
number	NULL
of	NULL
B	NULL
lymphocytes	NULL
(	NULL
B	NULL
cells	NULL
)	NULL
.	NULL

Preparation	NULL
and	NULL
analysis	NULL
of	NULL
bone	NULL
marrow	NULL
cells	NULL
from	NULL
the	NULL
chimeric	NULL
mice	NULL
indicated	NULL
that	NULL
the	NULL
bone	NULL
marrow	NULL
is	NULL
the	NULL
effective	NULL
site	NULL
for	NULL
specific	NULL
depletion	NULL
of	NULL
the	NULL
B-cell	NULL
population	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
transgenic	NULL
bone	NULL
marrow	NULL
cells	NULL
cocultured	NULL
with	NULL
a	NULL
bone	NULL
marrow-derived	NULL
stromal	NULL
cell	NULL
line	NULL
revealed	NULL
an	NULL
altered	NULL
B-cell	NULL
maturation	NULL
pattern	NULL
.	NULL

Cytokines	NULL
represent	NULL
a	NULL
class	NULL
of	NULL
soluble	NULL
mediators	NULL
that	NULL
affect	NULL
various	NULL
aspects	NULL
of	NULL
cellular	NULL
responses	NULL
such	NULL
as	NULL
stimulation	NULL
and	NULL
inhibition	NULL
of	NULL
proliferation	NULL
and	NULL
induction	NULL
of	NULL
differentiation	NULL
.	NULL

Each	NULL
cytokine	NULL
delivers	NULL
signals	NULL
through	NULL
specific	NULL
cognate	NULL
receptors	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Despite	NULL
extensive	NULL
characterization	NULL
of	NULL
the	NULL
structure	NULL
and	NULL
function	NULL
of	NULL
many	NULL
cytokines	NULL
and	NULL
their	NULL
receptors	NULL
,	NULL
the	NULL
molecular	NULL
mechanism	NULL
by	NULL
which	NULL
cytokine-mediated	NULL
signal	NULL
transduction	NULL
leads	NULL
to	NULL
cellular	NULL
responses	NULL
still	NULL
remains	NULL
unclear	NULL
,	NULL
especially	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
nuclear	NULL
events	NULL
that	NULL
would	NULL
control	NULL
the	NULL
fate	NULL
of	NULL
responding	NULL
cells	NULL
.	NULL

Interferons	NULL
(	NULL
IFNs	NULL
)	NULL
have	NULL
been	NULL
originally	NULL
identified	NULL
in	NULL
the	NULL
context	NULL
of	NULL
host	NULL
defense	NULL
mechanisms	NULL
against	NULL
viral	NULL
infection	NULL
(	NULL
3-5	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
all	NULL
IFN	NULL
species-i.e	NULL
.	NULL

,	NULL
type	NULL
I	NULL
IFNs	NULL
(	NULL
IFN-a	NULL
and	NULL
IFN-	NULL
$	NULL
8	NULL
)	NULL
,	NULL
and	NULL
type	NULL
II	NULL
IFN	NULL
(	NULL
IFN-y	NULL
)	NULL
-elicit	NULL
potent	NULL
antiviral	NULL
activity	NULL
of	NULL
their	NULL
target	NULL
cells	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
they	NULL
also	NULL
manifest	NULL
other	NULL
biological	NULL
activities	NULL
like	NULL
many	NULL
other	NULL
cytokines	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
much	NULL
attention	NULL
has	NULL
been	NULL
focused	NULL
on	NULL
IFNs	NULL
functioning	NULL
as	NULL
potent	NULL
inhibitors	NULL
of	NULL
cell	NULL
proliferation	NULL
,	NULL
thus	NULL
playing	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
the	NULL
growth	NULL
control	NULL
of	NULL
normal	NULL
and	NULL
transformed	NULL
cells	NULL
(	NULL
5-10	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
IFNs	NULL
belong	NULL
to	NULL
the	NULL
family	NULL
of	NULL
``	NULL
negative	NULL
growth	NULL
factors	NULL
.	NULL
``	NULL

In	NULL
fact	NULL
,	NULL
frequent	NULL
deletion	NULL
of	NULL
the	NULL
type	NULL
I	NULL
IFN	NULL
loci	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
some	NULL
malignancies	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

Such	NULL
observations	NULL
may	NULL
lend	NULL
support	NULL
to	NULL
the	NULL
prevailing	NULL
notion	NULL
that	NULL
cells	NULL
that	NULL
fail	NULL
to	NULL
produce	NULL
negative	NULL
growth	NULL
factors	NULL
or	NULL
respond	NULL
to	NULL
them	NULL
are	NULL
prone	NULL
to	NULL
acquire	NULL
malignant	NULL
pheno-types	NULL
(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

532	NULL
During	NULL
the	NULL
course	NULL
of	NULL
our	NULL
study	NULL
on	NULL
the	NULL
regulation	NULL
of	NULL
type	NULL
I	NULL
IFN	NULL
gene	NULL
expression	NULL
,	NULL
we	NULL
identified	NULL
and	NULL
cloned	NULL
nuclear	NULL
factor	NULL
,	NULL
termed	NULL
IRF-1	NULL
(	NULL
IFN	NULL
regulatory	NULL
factor	NULL
1	NULL
)	NULL
,	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
upstream	NULL
cis	NULL
elements	NULL
of	NULL
both	NULL
IFN-a	NULL
and	NULL
IFN-	NULL
genes	NULL
(	NULL
14-16	NULL
)	NULL
.	NULL

A	NULL
series	NULL
of	NULL
IRF-1	NULL
cDNA	NULL
expression	NULL
studies	NULL
revealed	NULL
IRF-1	NULL
functioning	NULL
as	NULL
a	NULL
transcriptional	NULL
activator	NULL
for	NULL
the	NULL
type	NULL
I	NULL
IFN	NULL
genes	NULL
(	NULL
17-19	NULL
)	NULL
.	NULL

Subsequently	NULL
,	NULL
another	NULL
factor	NULL
IRF-2	NULL
has	NULL
been	NULL
identified	NULL
that	NULL
apparently	NULL
antagonizes	NULL
the	NULL
IRF-1	NULL
effect	NULL
by	NULL
competing	NULL
for	NULL
the	NULL
same	NULL
cis	NULL
elements	NULL
(	NULL
18	NULL
)	NULL
.	NULL

It	NULL
was	NULL
then	NULL
found	NULL
that	NULL
expression	NULL
of	NULL
the	NULL
IRF-1	NULL
gene	NULL
(	NULL
as	NULL
well	NULL
as	NULL
the	NULL
IRF-2	NULL
gene	NULL
)	NULL
itself	NULL
is	NULL
induced	NULL
not	NULL
only	NULL
by	NULL
viruses	NULL
,	NULL
but	NULL
also	NULL
by	NULL
the	NULL
IFNs	NULL
;	NULL
the	NULL
IRF-1	NULL
gene	NULL
is	NULL
otherwise	NULL
expressed	NULL
only	NULL
at	NULL
very	NULL
low	NULL
levels	NULL
(	NULL
a	NULL
few	NULL
mRNA	NULL
copies	NULL
per	NULL
cell	NULL
;	NULL
refs	NULL
.	NULL

18	NULL
and	NULL
20	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
IRF	NULL
binding	NULL
sites	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
a	NULL
number	NULL
of	NULL
IFN-inducible	NULL
genes	NULL
(	NULL
16	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
sites	NULL
indeed	NULL
fall	NULL
in	NULL
the	NULL
sequences	NULL
that	NULL
were	NULL
originally	NULL
identified	NULL
as	NULL
IFN-response	NULL
sequences	NULL
within	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
those	NULL
genes	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
has	NULL
been	NULL
assumed	NULL
that	NULL
cellular	NULL
responses	NULL
to	NULL
IFNs	NULL
are	NULL
mediated	NULL
at	NULL
least	NULL
in	NULL
part	NULL
by	NULL
the	NULL
IFN-inducible	NULL
IRF-1	NULL
(	NULL
18	NULL
,	NULL
20	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
IFNs	NULL
function	NULL
as	NULL
negative	NULL
growth	NULL
factors	NULL
and	NULL
that	NULL
the	NULL
IRF-1	NULL
gene	NULL
is	NULL
IFN	NULL
inducible	NULL
raises	NULL
an	NULL
interesting	NULL
issue	NULL
concerning	NULL
whether	NULL
IRF-1	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
IFN-mediated	NULL
cellular	NULL
response	NULL
;	NULL
that	NULL
is	NULL
,	NULL
the	NULL
regulation	NULL
of	NULL
cell	NULL
growth	NULL
.	NULL

In	NULL
this	NULL
context	NULL
,	NULL
IRF-1	NULL
might	NULL
cause	NULL
cell	NULL
growth	NULL
inhibition	NULL
by	NULL
affecting	NULL
expression	NULL
of	NULL
the	NULL
IFN	NULL
genes	NULL
and/or	NULL
genes	NULL
that	NULL
are	NULL
directly	NULL
involved	NULL
in	NULL
cell	NULL
growth	NULL
inhibition	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
the	NULL
human	NULL
IRF-1	NULL
gene	NULL
has	NULL
recently	NULL
been	NULL
assigned	NULL
to	NULL
human	NULL
chromosome	NULL
5q23-31	NULL
by	NULL
restriction	NULL
fragment	NULL
length	NULL
polymorphism	NULL
linkage	NULL
analysis	NULL
(	NULL
S.1	NULL
.	NULL

,	NULL
H.	NULL
Harada	NULL
,	NULL
and	NULL
Y.	NULL
Nakamura	NULL
,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
this	NULL
region	NULL
has	NULL
been	NULL
termed	NULL
the	NULL
``	NULL
critical	NULL
region	NULL
,	NULL
``	NULL
which	NULL
is	NULL
frequently	NULL
deleted	NULL
in	NULL
some	NULL
myeloid	NULL
disorders	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
observation	NULL
has	NULL
raised	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
cells	NULL
that	NULL
fail	NULL
to	NULL
respond	NULL
to	NULL
IFNs	NULL
include	NULL
those	NULL
lacking	NULL
the	NULL
IRF-1	NULL
gene	NULL
.	NULL

As	NULL
an	NULL
approach	NULL
to	NULL
assess	NULL
the	NULL
possible	NULL
role	NULL
of	NULL
IRF-1	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
,	NULL
we	NULL
generated	NULL
transgenic	NULL
mice	NULL
carrying	NULL
the	NULL
human	NULL
IRF-1	NULL
gene	NULL
whose	NULL
con-stitutive	NULL
and	NULL
high	NULL
level	NULL
expression	NULL
is	NULL
driven	NULL
by	NULL
the	NULL
juxtaposed	NULL
human	NULL
immunoglobulin	NULL
heavy-chain	NULL
enhancer	NULL
(	NULL
E	NULL
,	NULL
,	NULL
)	NULL
.	NULL

We	NULL
report	NULL
that	NULL
such	NULL
transgenic	NULL
mice	NULL
show	NULL
a	NULL
dramatic	NULL
reduction	NULL
in	NULL
B	NULL
lymphocyte	NULL
(	NULL
B	NULL
cell	NULL
)	NULL
population	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Construction	NULL
of	NULL
the	NULL
E	NULL
,	NULL
,	NULL
IRF-1	NULL
Gene	NULL
and	NULL
Production	NULL
of	NULL
Transgenic	NULL
Mice	NULL
.	NULL

The	NULL
2.1-kilobase	NULL
(	NULL
kb	NULL
)	NULL
Xba	NULL
I	NULL
fragment	NULL
con	NULL
Abbreviations	NULL
:	NULL
IFN	NULL
,	NULL
interferon	NULL
;	NULL
IRF	NULL
,	NULL
IFN	NULL
regulatory	NULL
factor	NULL
;	NULL
E	NULL
,	NULL
,	NULL
,	NULL
immunoglobulin	NULL
heavy-chain	NULL
enhancer	NULL
;	NULL
FACS	NULL
,	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
;	NULL
PFC	NULL
,	NULL
plaque-forming	NULL
cell	NULL
;	NULL
SRBC	NULL
,	NULL
sheep	NULL
eryth-rocyte	NULL
;	NULL
CFU	NULL
,	NULL
colony-forming	NULL
unit	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
PBL	NULL
,	NULL
peripheral	NULL
blood	NULL
lymphocyte	NULL
.	NULL

Immunology	NULL
:	NULL
Yamada	NULL
et	NULL
al	NULL
.	NULL

HHH	NULL
1	NULL
2	NULL
3	NULL
4	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
(	NULL
1991	NULL
)	NULL
533	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
A	NULL
--	NULL
A	NULL
1	NULL
kb	NULL
k	NULL
--	NULL
--	NULL
--	NULL
A	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

-	NULL
Schematic	NULL
representation	NULL
of	NULL
the	NULL
injected	NULL
transgene	NULL
fragment	NULL
carrying	NULL
the	NULL
human	NULL
IRF-1	NULL
gene	NULL
and	NULL
the	NULL
human	NULL
E	NULL
,	NULL
,	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Solid	NULL
boxes	NULL
represent	NULL
exons	NULL
of	NULL
the	NULL
human	NULL
IRF-1	NULL
gene	NULL
with	NULL
the	NULL
number	NULL
of	NULL
each	NULL
exon	NULL
given	NULL
above	NULL
.	NULL

The	NULL
human	NULL
IRF-1	NULL
gene	NULL
contains	NULL
an	NULL
11.5-kb	NULL
sequence	NULL
downstream	NULL
of	NULL
its	NULL
last	NULL
exon	NULL
.	NULL

taining	NULL
E	NULL
,	NULL
,	NULL
(	NULL
derived	NULL
from	NULL
cU23	NULL
;	NULL
ref	NULL
.	NULL

24	NULL
)	NULL
and	NULL
the	NULL
19-kb	NULL
human	NULL
IRF-1	NULL
gene	NULL
EcoRI	NULL
fragment	NULL
(	NULL
derived	NULL
from	NULL
A	NULL
human	NULL
IRF-1B	NULL
;	NULL
S.1	NULL
.	NULL

,	NULL
H.	NULL
Harada	NULL
,	NULL
and	NULL
M.	NULL
Maruyama	NULL
,	NULL
unpublished	NULL
data	NULL
)	NULL
were	NULL
subsequently	NULL
subcloned	NULL
into	NULL
the	NULL
Xba	NULL
I	NULL
and	NULL
Sma	NULL
I	NULL
sites	NULL
of	NULL
pUC19	NULL
,	NULL
respectively	NULL
.	NULL

(	NULL
The	NULL
EcoRI	NULL
site	NULL
was	NULL
converted	NULL
to	NULL
a	NULL
blunt	NULL
end	NULL
prior	NULL
to	NULL
ligation	NULL
and	NULL
the	NULL
site	NULL
was	NULL
not	NULL
restored	NULL
after	NULL
ligation	NULL
.	NULL
)	NULL

The	NULL
resultant	NULL
plasmid	NULL
was	NULL
digested	NULL
by	NULL
EcoRI	NULL
and	NULL
Sal	NULL
I	NULL
to	NULL
obtain	NULL
the	NULL
entire	NULL
transgene	NULL
fragment	NULL
(	NULL
E	NULL
,	NULL
,	NULL
-IRF-1	NULL
)	NULL
and	NULL
was	NULL
used	NULL
for	NULL
microinjection	NULL
.	NULL

The	NULL
schematic	NULL
construction	NULL
of	NULL
the	NULL
E	NULL
,	NULL
,	NULL
-IRF-1	NULL
gene	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Transgenic	NULL
mice	NULL
were	NULL
produced	NULL
as	NULL
described	NULL
(	NULL
25	NULL
)	NULL
by	NULL
using	NULL
C57BL/6	NULL
mice	NULL
purchased	NULL
from	NULL
Nippon	NULL
Clea	NULL
(	NULL
Osaka	NULL
)	NULL
.	NULL

RNA	NULL
Blotting	NULL
Analysis	NULL
.	NULL

RNA	NULL
blotting	NULL
analysis	NULL
was	NULL
carried	NULL
out	NULL
following	NULL
described	NULL
procedures	NULL
(	NULL
26	NULL
)	NULL
.	NULL

The	NULL
Sac	NULL
I/Kpn	NULL
I	NULL
fragment	NULL
from	NULL
the	NULL
human	NULL
IRF-1	NULL
cDNA	NULL
clone	NULL
pHIRF31	NULL
(	NULL
27	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

Fluorescence-Activated	NULL
Cell	NULL
Sorter	NULL
(	NULL
FACS	NULL
)	NULL
Analysis	NULL
.	NULL

Half	NULL
a	NULL
million	NULL
cells	NULL
from	NULL
various	NULL
lymphoid	NULL
tissues	NULL
were	NULL
stained	NULL
with	NULL
either	NULL
fluorescein-conjugated	NULL
or	NULL
phycocyanin-conjugated	NULL
monoclonal	NULL
antibodies	NULL
RA3-6B2	NULL
(	NULL
anti-B220	NULL
;	NULL
ref	NULL
.	NULL

28	NULL
)	NULL
,	NULL
30H12	NULL
(	NULL
anti-Thy1.2	NULL
;	NULL
ref	NULL
.	NULL

29	NULL
)	NULL
,	NULL
53-6	NULL
(	NULL
anti-Lyt-2	NULL
;	NULL
ref	NULL
.	NULL

30	NULL
)	NULL
,	NULL
GK1.5	NULL
(	NULL
anti-L3T4	NULL
;	NULL
ref	NULL
.	NULL

31	NULL
)	NULL
and	NULL
analyzed	NULL
by	NULL
a	NULL
dual-laser	NULL
FACS	NULL
440	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
equipped	NULL
with	NULL
an	NULL
argon	NULL
ion	NULL
laser	NULL
and	NULL
a	NULL
dye	NULL
laser	NULL
(	NULL
32	NULL
)	NULL
.	NULL

In	NULL
Vitro	NULL
Assay	NULL
of	NULL
Mitogen-Induced	NULL
Spleen	NULL
Cell	NULL
Proliferation	NULL
and	NULL
Plaque-Forming	NULL
Cell	NULL
(	NULL
PFC	NULL
)	NULL
Assay	NULL
.	NULL

Spleen	NULL
cells	NULL
were	NULL
isolated	NULL
and	NULL
cultured	NULL
with	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
plus	NULL
ConA	NULL
(	NULL
Pharmacia	NULL
)	NULL
or	NULL
lipopolysaccharide	NULL
(	NULL
Difco	NULL
)	NULL
with	NULL
the	NULL
cell	NULL
concentration	NULL
of	NULL
2	NULL
x	NULL
10°	NULL
cells	NULL
per	NULL
well	NULL
in	NULL
96-well	NULL
flat-bottomed	NULL
microculture	NULL
plates	NULL
.	NULL

After	NULL
36	NULL
hr	NULL
of	NULL
culture	NULL
,	NULL
1	NULL
Ci	NULL
(	NULL
1	NULL
Ci	NULL
=	NULL
37	NULL
GBq	NULL
)	NULL
of	NULL
[	NULL
}	NULL
H	NULL
]	NULL
thymidine	NULL
was	NULL
added	NULL
to	NULL
each	NULL
well	NULL
,	NULL
incubation	NULL
was	NULL
continued	NULL
for	NULL
another	NULL
12	NULL
hr	NULL
,	NULL
and	NULL
[	NULL
»	NULL
HJthymidine	NULL
incorporation	NULL
was	NULL
measured	NULL
.	NULL

The	NULL
measurement	NULL
of	NULL
'the	NULL
PFC	NULL
was	NULL
as	NULL
described	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Eight	NULL
days	NULL
after	NULL
immunization	NULL
of	NULL
sheep	NULL
erythrocytes	NULL
(	NULL
SRBCs	NULL
)	NULL
(	NULL
500	NULL
ul	NULL
;	NULL
10	NULL
%	NULL
packed	NULL
vol	NULL
)	NULL
and	NULL
after	NULL
another	NULL
2	NULL
days	NULL
of	NULL
booster	NULL
injections	NULL
,	NULL
spleen	NULL
cells	NULL
were	NULL
isolated	NULL
and	NULL
tested	NULL
for	NULL
the	NULL
number	NULL
of	NULL
anti-SRBC	NULL
PFCs	NULL
by	NULL
a	NULL
direct	NULL
method	NULL
.	NULL

pa	NULL
)	NULL
oo|	NULL
mo	NULL
]	NULL
B220	NULL
rh	NULL
)	NULL
Lon	NULL
HSA	NULL
jo	NULL
B220	NULL
,	NULL
1	NULL
10	NULL
100	NULL
1	NULL
10	NULL
10	NULL
1	NULL
10	NULL
100	NULL
Thy	NULL
1.2	NULL
Thy	NULL
1.2	NULL
Thy	NULL
1.2	NULL
B220	NULL
,	NULL
.	NULL

Preparation	NULL
of	NULL
Bone	NULL
Marrow	NULL
Chimeric	NULL
Mice	NULL
.	NULL

Bone	NULL
marrow	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
either	NULL
transgenic	NULL
or	NULL
littermate	NULL
mice	NULL
and	NULL
8	NULL
x	NULL
10°	NULL
cells	NULL
were	NULL
injected	NULL
intravenously	NULL
into	NULL
lethally	NULL
irradiated	NULL
(	NULL
880	NULL
rad	NULL
by	NULL
a	NULL
Cs	NULL
source	NULL
;	NULL
1	NULL
rad	NULL
=	NULL
0.01	NULL
Gy	NULL
)	NULL
8-week-old	NULL
C57BL/6	NULL
mice	NULL
;	NULL
the	NULL
lymphoid	NULL
cells	NULL
were	NULL
analyzed	NULL
for	NULL
surface	NULL
marker	NULL
expression	NULL
8	NULL
weeks	NULL
after	NULL
reconstitution	NULL
.	NULL

Analysis	NULL
of	NULL
B-Cell	NULL
Precursor	NULL
Frequency	NULL
and	NULL
Colony-Forming	NULL
Unit-Interleukin	NULL
7	NULL
(	NULL
CFU-IL-7	NULL
)	NULL
Frequency	NULL
from	NULL
Bone	NULL
Marrow	NULL
Cells	NULL
.	NULL

Analysis	NULL
of	NULL
B-cell	NULL
precursor	NULL
frequency	NULL
and	NULL
CFU-IL-7	NULL
frequency	NULL
was	NULL
as	NULL
described	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
a	NULL
96-well	NULL
microculture	NULL
plate	NULL
seeded	NULL
with	NULL
a	NULL
subconfluent	NULL
layer	NULL
of	NULL
stromal	NULL
cell	NULL
line	NULL
PA6	NULL
was	NULL
prepared	NULL
and	NULL
10°	NULL
bone	NULL
marrow	NULL
cells	NULL
were	NULL
overlaid	NULL
with	NULL
IL-7	NULL
(	NULL
20	NULL
units/ml	NULL
)	NULL
and	NULL
cultured	NULL
for	NULL
12	NULL
days	NULL
.	NULL

Wells	NULL
containing	NULL
pre-B	NULL
cells	NULL
(	NULL
identified	NULL
as	NULL
B220-positive	NULL
cells	NULL
by	NULL
FACS	NULL
analysis	NULL
)	NULL
were	NULL
scored	NULL
and	NULL
frequency	NULL
was	NULL
determined	NULL
based	NULL
on	NULL
a	NULL
Poisson	NULL
distribution	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

CFU-IL-7	NULL
or	NULL
CFU-IL-3	NULL
colonies	NULL
were	NULL
obtained	NULL
after	NULL
7	NULL
days	NULL
of	NULL
culture	NULL
of	NULL
2	NULL
x	NULL
10+	NULL
bone	NULL
marrow	NULL
cells	NULL
seeded	NULL
on	NULL
methyl-cellulose	NULL
plates	NULL
with	NULL
IL-7	NULL
(	NULL
10	NULL
units/ml	NULL
)	NULL
or	NULL
IL-3	NULL
(	NULL
200	NULL
units/m1	NULL
)	NULL
.	NULL

Recombinant	NULL
IL-3	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Y.	NULL
Sudo	NULL
(	NULL
Bio-material	NULL
Research	NULL
Institute	NULL
,	NULL
Yokohama	NULL
,	NULL
Japan	NULL
)	NULL
and	NULL
recombinant	NULL
IL-7	NULL
was	NULL
prepared	NULL
as	NULL
described	NULL
(	NULL
35	NULL
)	NULL
.	NULL

RESULTS	NULL
Establishment	NULL
of	NULL
Transgenic	NULL
Mice	NULL
Containing	NULL
the	NULL
Human	NULL
IRF-1	NULL
Gene	NULL
Linked	NULL
with	NULL
the	NULL
Human	NULL
E	NULL
,	NULL
,	NULL
.	NULL

The	NULL
structure	NULL
of	NULL
the	NULL
injected	NULL
DNA	NULL
fragment	NULL
is	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

It	NULL
comprises	NULL
the	NULL
entire	NULL
human	NULL
IRF-1	NULL
gene	NULL
with	NULL
its	NULL
10	NULL
exons	NULL
and	NULL
5	NULL
'	NULL
flanking	NULL
sequence	NULL
extending	NULL
455	NULL
base	NULL
pairs	NULL
from	NULL
the	NULL
major	NULL
cap	NULL
site	NULL
(	NULL
S.1	NULL
.	NULL

,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

The	NULL
IRF-1	NULL
gene	NULL
was	NULL
linked	NULL
with	NULL
the	NULL
human	NULL
E	NULL
,	NULL
,	NULL
(	NULL
24	NULL
)	NULL
with	NULL
the	NULL
expectation	NULL
that	NULL
the	NULL
IRF-1	NULL
gene	NULL
would	NULL
be	NULL
specifically	NULL
expressed	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

The	NULL
resulting	NULL
DNA	NULL
fragment	NULL
encompassing	NULL
21	NULL
kb	NULL
was	NULL
microinjected	NULL
into	NULL
CS57BL/6-derived	NULL
fertilized	NULL
eggs	NULL
and	NULL
transferred	NULL
to	NULL
oviducts	NULL
of	NULL
pseudopregnant	NULL
ICR	NULL
mice	NULL
.	NULL

Among	NULL
the	NULL
41	NULL
offspring	NULL
,	NULL
3	NULL
mice	NULL
were	NULL
shown	NULL
to	NULL
be	NULL
positive	NULL
for	NULL
transgene	NULL
integration	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Line	NULL
7	NULL
(	NULL
about	NULL
a	NULL
3-copy	NULL
integrant	NULL
)	NULL
was	NULL
mainly	NULL
used	NULL
for	NULL
(	NULL
£	NULL
)	NULL
he	NULL
)	NULL
i001	NULL
|	NULL
B220	NULL
,	NULL
L3T4	NULL
_	NULL
,	NULL
,	NULL
Thy	NULL
1.2	NULL
|	NULL
Thy	NULL
1.2	NULL
°°	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Two-color	NULL
FACS	NULL
analysis	NULL
for	NULL
cell-surface	NULL
marker	NULL
expression	NULL
(	NULL
B220	NULL
,	NULL
Thy1.2	NULL
,	NULL
L3T4	NULL
,	NULL
Lyt-2	NULL
antigens	NULL
)	NULL
of	NULL
various	NULL
lymphoid	NULL
cells	NULL
from	NULL
transgenic	NULL
(	NULL
a-f	NULL
)	NULL
or	NULL
littermate	NULL
(	NULL
g-/	NULL
)	NULL
mice	NULL
.	NULL

(	NULL
a	NULL
and	NULL
g	NULL
)	NULL
Staining	NULL
pattern	NULL
spleen	NULL
cells	NULL
.	NULL

(	NULL
b	NULL
and	NULL
A	NULL
)	NULL
PBLs	NULL
.	NULL

(	NULL
c	NULL
and	NULL
i	NULL
)	NULL
Lymph	NULL
node	NULL
cells	NULL
.	NULL

(	NULL
d	NULL
and	NULL
j	NULL
)	NULL
Bone	NULL
marrow	NULL
cells	NULL
.	NULL

(	NULL
e	NULL
,	NULL
f	NULL
,	NULL
k	NULL
,	NULL
and	NULL
/	NULL
)	NULL
Thymocytes	NULL
.	NULL

534	NULL
Immunology	NULL
:	NULL
Yamada	NULL
et	NULL
al	NULL
.	NULL

4	NULL
i	NULL
-	NULL
285	NULL
ﬂ	NULL
'	NULL
.	NULL

<	NULL
18S	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

-	NULL
Analysis	NULL
of	NULL
the	NULL
human	NULL
IRF-l-specific	NULL
transcript	NULL
in	NULL
vari-	NULL
ous	NULL
tissues	NULL
of	NULL
transgenic	NULL
(	NULL
lanes	NULL
3-6	NULL
)	NULL
and	NULL
littermate	NULL
(	NULL
lanes	NULL
7-10	NULL
)	NULL
mice	NULL
.	NULL

Each	NULL
lane	NULL
contains	NULL
5	NULL
ug	NULL
of	NULL
total	NULL
RNA	NULL
from	NULL
the	NULL
following	NULL
cells	NULL
:	NULL
Lane	NULL
1	NULL
,	NULL
FL	NULL
cells	NULL
treated	NULL
with	NULL
Newcastle	NULL
disease	NULL
virus	NULL
(	NULL
NDV	NULL
)	NULL
for	NULL
15	NULL
hr	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
L929	NULL
cells	NULL
treated	NULL
with	NULL
NDV	NULL
virus	NULL
for	NULL
9	NULL
hr	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
liver	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
thymus	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
spleen	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
bone	NULL
marrow	NULL
;	NULL
lane	NULL
7	NULL
,	NULL
liver	NULL
;	NULL
lane	NULL
8	NULL
,	NULL
thymus	NULL
;	NULL
lane	NULL
9	NULL
,	NULL
spleen	NULL
;	NULL
lane	NULL
10	NULL
,	NULL
bone	NULL
marrow	NULL
.	NULL

this	NULL
study	NULL
.	NULL

However	NULL
,	NULL
another	NULL
line	NULL
,	NULL
5-2	NULL
(	NULL
about	NULL
a	NULL
1l-copy	NULL
integrant	NULL
)	NULL
gave	NULL
essentially	NULL
the	NULL
same	NULL
results	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

B-Cell	NULL
Population	NULL
Is	NULL
Dramatically	NULL
Reduced	NULL
in	NULL
All	NULL
Lymphoid	NULL
Tissues	NULL
of	NULL
Transgenic	NULL
Mice	NULL
.	NULL

The	NULL
lymphocyte	NULL
subset	NULL
of	NULL
these	NULL
transgenic	NULL
and	NULL
littermate	NULL
mice	NULL
was	NULL
examined	NULL
by	NULL
two-color	NULL
FACS	NULL
analysis	NULL
.	NULL

Fig	NULL
.	NULL

2	NULL
shows	NULL
the	NULL
results	NULL
of	NULL
the	NULL
two-color	NULL
FACS	NULL
analysis	NULL
of	NULL
the	NULL
various	NULL
lymphoid	NULL
tissue	NULL
cells	NULL
stained	NULL
with	NULL
the	NULL
pan	NULL
B-cell	NULL
marker	NULL
anti-B220	NULL
,	NULL
and	NULL
the	NULL
pan	NULL
T-cell	NULL
marker	NULL
anti-Thy1.2	NULL
.	NULL

The	NULL
B220-positive	NULL
B-cell	NULL
fraction	NULL
was	NULL
dramatically	NULL
reduced	NULL
in	NULL
spleen	NULL
(	NULL
Fig	NULL
.	NULL

2a	NULL
)	NULL
,	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
PBLs	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2b	NULL
)	NULL
,	NULL
lymph	NULL
node	NULL
(	NULL
mesenchymal	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2¢c	NULL
)	NULL
,	NULL
and	NULL
bone	NULL
marrow	NULL
(	NULL
Fig	NULL
.	NULL

2d	NULL
)	NULL
of	NULL
the	NULL
transgenic	NULL
mice	NULL
.	NULL

In	NULL
the	NULL
spleen	NULL
,	NULL
B220-positive	NULL
B	NULL
cells	NULL
constituted	NULL
only	NULL
~1	NULL
%	NULL
of	NULL
the	NULL
total	NULL
cell	NULL
population	NULL
in	NULL
the	NULL
transgenic	NULL
line	NULL
,	NULL
whereas	NULL
in	NULL
littermates	NULL
68	NULL
%	NULL
were	NULL
B220	NULL
positive	NULL
(	NULL
Fig	NULL
.	NULL

2g	NULL
)	NULL
.	NULL

In	NULL
PBLs	NULL
and	NULL
lymph	NULL
nodes	NULL
,	NULL
the	NULL
B220-positive	NULL
cells	NULL
constituted	NULL
<	NULL
1	NULL
%	NULL
in	NULL
the	NULL
transgenic	NULL
line	NULL
.	NULL

However	NULL
,	NULL
in	NULL
bone	NULL
marrow	NULL
,	NULL
a	NULL
significant	NULL
number	NULL
of	NULL
cells	NULL
(	NULL
21	NULL
%	NULL
)	NULL
were	NULL
B220	NULL
positive	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
the	NULL
transgenic	NULL
mice	NULL
are	NULL
devoid	NULL
of	NULL
most	NULL
B220-positive	NULL
B	NULL
cells	NULL
in	NULL
all	NULL
the	NULL
lymphoid	NULL
tissues	NULL
except	NULL
bone	NULL
marrow	NULL
suggests	NULL
that	NULL
bone	NULL
marrow	NULL
may	NULL
be	NULL
primarily	NULL
responsible	NULL
for	NULL
the	NULL
reduction	NULL
,	NULL
since	NULL
this	NULL
is	NULL
where	NULL
B-cell	NULL
differentiation	NULL
initiates	NULL
(	NULL
36	NULL
,	NULL
37	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
bone	NULL
marrow	NULL
chimeric	NULL
mice	NULL
reconstituted	NULL
by	NULL
the	NULL
transgenic	NULL
bone	NULL
marrow	NULL
cells	NULL
also	NULL
supported	NULL
this	NULL
view	NULL
(	NULL
see	NULL
below	NULL
and	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Subsequently	NULL
,	NULL
14	NULL
Fj	NULL
transgenic	NULL
offspring	NULL
and	NULL
littermates	NULL
from	NULL
line	NULL
7	NULL
were	NULL
analyzed	NULL
for	NULL
their	NULL
lymphocyte	NULL
subset	NULL
SRBC	NULL
_._	NULL
,	NULL
|	NULL
_J	NULL
__	NULL
_	NULL
__	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
(	NULL
1991	NULL
)	NULL
composition	NULL
,	NULL
revealing	NULL
that	NULL
the	NULL
B-cell-specific	NULL
reduction	NULL
is	NULL
perfectly	NULL
concordant	NULL
with	NULL
the	NULL
transmission	NULL
of	NULL
the	NULL
transgene	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
other	NULL
transgenic	NULL
mouse	NULL
line	NULL
5-2	NULL
gave	NULL
similar	NULL
findings	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
specific	NULL
reduction	NULL
in	NULL
the	NULL
B-cell	NULL
population	NULL
is	NULL
not	NULL
due	NULL
to	NULL
the	NULL
effect	NULL
of	NULL
integration	NULL
of	NULL
the	NULL
transgene	NULL
into	NULL
a	NULL
specific	NULL
site	NULL
on	NULL
host	NULL
chromosomes	NULL
.	NULL

No	NULL
particular	NULL
change	NULL
in	NULL
the	NULL
T-cell	NULL
subpopulations	NULL
expressing	NULL
surface	NULL
markers	NULL
such	NULL
as	NULL
Thy1.2	NULL
,	NULL
L3T4	NULL
(	NULL
CD4	NULL
)	NULL
,	NULL
and	NULL
Lyt-2	NULL
(	NULL
CD8	NULL
)	NULL
were	NULL
observed	NULL
in	NULL
the	NULL
thymus	NULL
of	NULL
transgenic	NULL
mice	NULL
when	NULL
compared	NULL
to	NULL
those	NULL
from	NULL
littermates	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Lymphocyte-Specific	NULL
Expression	NULL
of	NULL
mRNA	NULL
for	NULL
the	NULL
Transgene	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
mRNA	NULL
from	NULL
the	NULL
transgene	NULL
in	NULL
various	NULL
tissues	NULL
by	NULL
Northern	NULL
blotting	NULL
analysis	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
various	NULL
tissues	NULL
and	NULL
hybridized	NULL
with	NULL
a	NULL
human	NULL
IRF-1-specific	NULL
probe	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
RNA	NULL
specific	NULL
for	NULL
the	NULL
transgene	NULL
was	NULL
expressed	NULL
constitutively	NULL
in	NULL
lymphoid	NULL
tissues	NULL
,	NULL
with	NULL
levels	NULL
highest	NULL
in	NULL
thymus	NULL
,	NULL
followed	NULL
by	NULL
bone	NULL
marrow	NULL
and	NULL
spleen	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Mitogenic	NULL
Response	NULL
of	NULL
the	NULL
Lymphocytes	NULL
and	NULL
Measurement	NULL
of	NULL
the	NULL
PFCs	NULL
in	NULL
Spleen	NULL
Cells	NULL
.	NULL

To	NULL
gain	NULL
insights	NULL
into	NULL
the	NULL
alterations	NULL
of	NULL
lymphocyte	NULL
function	NULL
in	NULL
transgenic	NULL
mice	NULL
,	NULL
responses	NULL
of	NULL
the	NULL
spleen	NULL
cells	NULL
to	NULL
B-cell-specific	NULL
mitogen	NULL
lipopolysaccharide	NULL
and	NULL
T-cell-specific	NULL
mitogen	NULL
(	NULL
ConA	NULL
)	NULL
were	NULL
examined	NULL
.	NULL

Spleen	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
a	NULL
transgenic	NULL
or	NULL
littermate	NULL
mouse	NULL
and	NULL
the	NULL
response	NULL
to	NULL
each	NULL
mitogen	NULL
was	NULL
measured	NULL
by	NULL
incorporation	NULL
of	NULL
[	NULL
*H	NULL
]	NULL
thymidine	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4a	NULL
,	NULL
the	NULL
magnitude	NULL
of	NULL
response	NULL
to	NULL
lipopolysaccharide	NULL
by	NULL
cells	NULL
from	NULL
the	NULL
transgenic	NULL
mouse	NULL
was	NULL
reduced	NULL
by	NULL
94	NULL
%	NULL
,	NULL
compared	NULL
to	NULL
that	NULL
of	NULL
similarly	NULL
treated	NULL
cells	NULL
from	NULL
the	NULL
littermate	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
no	NULL
evident	NULL
difference	NULL
was	NULL
detected	NULL
for	NULL
the	NULL
ConA	NULL
response	NULL
between	NULL
the	NULL
two	NULL
groups	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
functional	NULL
status	NULL
of	NULL
the	NULL
humoral	NULL
immune	NULL
response	NULL
,	NULL
numbers	NULL
of	NULL
antibody-producing	NULL
cells	NULL
for	NULL
SRBCs	NULL
were	NULL
measured	NULL
by	NULL
hemolytic	NULL
PFC	NULL
assay	NULL
in	NULL
the	NULL
spleen	NULL
cells	NULL
from	NULL
SRBC	NULL
immunized	NULL
or	NULL
nonimmunized	NULL
,	NULL
transgenic	NULL
or	NULL
littermate	NULL
mice	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

46	NULL
,	NULL
the	NULL
numbers	NULL
of	NULL
anti-SRBC	NULL
antibody-producing	NULL
cells	NULL
were	NULL
dramatically	NULL
lower	NULL
in	NULL
the	NULL
transgenic	NULL
line	NULL
compared	NULL
to	NULL
the	NULL
littermates	NULL
.	NULL

Bone	NULL
Marrow	NULL
Is	NULL
Primarily	NULL
Responsible	NULL
for	NULL
the	NULL
Reduction	NULL
in	NULL
the	NULL
B-Cell	NULL
Fraction	NULL
.	NULL

As	NULL
the	NULL
human	NULL
E	NULL
,	NULL
,	NULL
was	NULL
linked	NULL
to	NULL
the	NULL
transgene	NULL
,	NULL
we	NULL
assumed	NULL
that	NULL
the	NULL
B-cell-specific	NULL
reduction	NULL
was	NULL
primarily	NULL
mediated	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
.	NULL

To	NULL
directly	NULL
examine	NULL
this	NULL
possibility	NULL
,	NULL
bone	NULL
marrow	NULL
chimeric	NULL
mice	NULL
were	NULL
made	NULL
and	NULL
analyzed	NULL
for	NULL
the	NULL
composition	NULL
of	NULL
their	NULL
lymphocyte	NULL
subset	NULL
.	NULL

Lethally	NULL
irradiated	NULL
(	NULL
880	NULL
rad	NULL
)	NULL
syngeneic	NULL
C57BL/6	NULL
mice	NULL
were	NULL
injected	NULL
intravenously	NULL
with	NULL
bone	NULL
marrow	NULL
cells	NULL
(	NULL
8	NULL
x	NULL
10°	NULL
cells	NULL
per	NULL
mouse	NULL
)	NULL
derived	NULL
from	NULL
either	NULL
a	NULL
transgenic	NULL
or	NULL
a	NULL
littermate	NULL
j	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Mitogen-induced	NULL
spleen	NULL
cell	NULL
|	NULL
proliferation	NULL
was	NULL
measured	NULL
by	NULL
uptake	NULL
of	NULL
j	NULL
PHIthymidine	NULL
@	NULL
H-TaR	NULL
)	NULL
.	NULL

Spleen	NULL
cells	NULL
were	NULL
E	NULL
isolated	NULL
from	NULL
either	NULL
transgenic	NULL
or	NULL
littermate	NULL
|	NULL
mice	NULL
and	NULL
stimulated	NULL
in	NULL
vitro	NULL
with	NULL
ConA	NULL
or	NULL
|	NULL
lypopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
for	NULL
2	NULL
days	NULL
and	NULL
then	NULL
pulsed	NULL
with	NULL
{	NULL
H	NULL
]	NULL
thymidine	NULL
for	NULL
12	NULL
hr	NULL
.	NULL

(	NULL
b	NULL
)	NULL
The	NULL
direct	NULL
PFC	NULL
assay	NULL
was	NULL
performed	NULL
following	NULL
described	NULL
procedures	NULL
(	NULL
33	NULL
)	NULL
and	NULL
using	NULL
unimmu-nized	NULL
or	NULL
immunized	NULL
spleen	NULL
cells	NULL
from	NULL
either	NULL
transgenic	NULL
or	NULL
littermate	NULL
mice	NULL
.	NULL

Immunology	NULL
:	NULL
Yamada	NULL
et	NULL
al	NULL
.	NULL

0	NULL
Thy	NULL
1.2	NULL
Thy	NULL
1.2	NULL
1	NULL
10	NULL
100	NULL
Thy	NULL
1.2	NULL
mouse	NULL
.	NULL

Eight	NULL
weeks	NULL
later	NULL
,	NULL
cells	NULL
from	NULL
lymphoid	NULL
tissues	NULL
were	NULL
analyzed	NULL
by	NULL
two-color	NULL
FACS	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

The	NULL
chimeric	NULL
mouse	NULL
reconstituted	NULL
with	NULL
transgenic	NULL
bone	NULL
marrow	NULL
cells	NULL
showed	NULL
a	NULL
similar	NULL
staining	NULL
pattern	NULL
as	NULL
the	NULL
transgenic	NULL
donor	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
the	NULL
B-cell	NULL
fraction	NULL
was	NULL
dramatically	NULL
reduced	NULL
in	NULL
the	NULL
spleen	NULL
,	NULL
PBLs	NULL
,	NULL
and	NULL
lymph	NULL
nodes	NULL
.	NULL

These	NULL
observations	NULL
indicate	NULL
that	NULL
transgenic	NULL
bone	NULL
marrow	NULL
is	NULL
primarily	NULL
responsible	NULL
for	NULL
the	NULL
depletion	NULL
of	NULL
B-lineage	NULL
cells	NULL
.	NULL

In	NULL
Vitro	NULL
Culture	NULL
of	NULL
Transgenic	NULL
Bone	NULL
Marrow	NULL
Cells	NULL
with	NULL
a	NULL
Bone	NULL
Marrow-Derived	NULL
Stromal	NULL
Cell	NULL
Line	NULL
.	NULL

Recently	NULL
,	NULL
bone	NULL
marrow-derived	NULL
stromal	NULL
cell	NULL
lines	NULL
were	NULL
established	NULL
by	NULL
several	NULL
groups	NULL
and	NULL
,	NULL
by	NULL
utilizing	NULL
those	NULL
cell	NULL
lines	NULL
,	NULL
at	NULL
least	NULL
part	NULL
of	NULL
the	NULL
B-cell	NULL
differentiation	NULL
could	NULL
be	NULL
reproduced	NULL
in	NULL
vitro	NULL
by	NULL
coculture	NULL
with	NULL
bone	NULL
marrow	NULL
cells	NULL
(	NULL
34	NULL
,	NULL
38-40	NULL
)	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
the	NULL
B-cell	NULL
differentiation	NULL
program	NULL
is	NULL
affected	NULL
in	NULL
transgenic	NULL
bone	NULL
marrow	NULL
,	NULL
bone	NULL
marrow	NULL
cells	NULL
were	NULL
coculti-vated	NULL
with	NULL
the	NULL
stromal	NULL
cell	NULL
line	NULL
PAG	NULL
(	NULL
34	NULL
)	NULL
and	NULL
IL-7	NULL
.	NULL

As	NULL
summarized	NULL
in	NULL
Table	NULL
1	NULL
,	NULL
the	NULL
frequency	NULL
of	NULL
pre-B-cell	NULL
generation	NULL
is	NULL
dramatically	NULL
lower	NULL
in	NULL
transgenic	NULL
bone	NULL
marrow	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
the	NULL
littermate	NULL
mouse	NULL
.	NULL

The	NULL
altered	NULL
B-cell	NULL
maturation	NULL
was	NULL
also	NULL
illustrated	NULL
by	NULL
the	NULL
CFU-IL-7-dependent	NULL
colony	NULL
formation	NULL
assay	NULL
(	NULL
Table	NULL
1	NULL
;	NULL
ref	NULL
.	NULL

41	NULL
)	NULL
.	NULL

The	NULL
CFU-IL-7	NULL
colony	NULL
formation	NULL
was	NULL
undetectable	NULL
in	NULL
the	NULL
transgenic	NULL
line	NULL
,	NULL
whereas	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
for	NULL
multicolony	NULL
formation	NULL
by	NULL
IL-3	NULL
(	NULL
CFU-IL-3	NULL
)	NULL
was	NULL
similar	NULL
in	NULL
transgenic	NULL
and	NULL
littermate	NULL
mice	NULL
,	NULL
indicating	NULL
that	NULL
hematopoiesis	NULL
is	NULL
not	NULL
affected	NULL
in	NULL
transgenic	NULL
mice	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

DISCUSSION	NULL
Much	NULL
attention	NULL
has	NULL
been	NULL
focused	NULL
on	NULL
IFNs	NULL
for	NULL
their	NULL
effects	NULL
on	NULL
growth	NULL
or	NULL
differentiation	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
hematopoietic	NULL
cells	NULL
,	NULL
IFN	NULL
treatment	NULL
of	NULL
normal	NULL
hematopoietic	NULL
cells	NULL
results	NULL
in	NULL
inhibition	NULL
of	NULL
growth	NULL
or	NULL
differentiation	NULL
(	NULL
5-10	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
aberrant	NULL
production	NULL
of	NULL
IFNs	NULL
was	NULL
found	NULL
to	NULL
be	NULL
accompanied	NULL
by	NULL
the	NULL
human	NULL
pathological	NULL
state	NULL
aplastic	NULL
anemia	NULL
,	NULL
suggesting	NULL
further	NULL
the	NULL
negative	NULL
effects	NULL
of	NULL
IFNs	NULL
in	NULL
cell	NULL
growth	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
(	NULL
1991	NULL
)	NULL
535	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Two-color	NULL
FACS	NULL
analysis	NULL
for	NULL
cell-surface	NULL
marker	NULL
expression	NULL
(	NULL
B220	NULL
and	NULL
Thy1.2	NULL
antigen	NULL
)	NULL
of	NULL
various	NULL
lymphoid	NULL
cells	NULL
from	NULL
chimeric	NULL
mice	NULL
reconstituted	NULL
by	NULL
either	NULL
transgenic	NULL
(	NULL
a-d	NULL
)	NULL
or	NULL
littermate	NULL
(	NULL
e-A	NULL
)	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

(	NULL
a	NULL
and	NULL
e	NULL
)	NULL
Spleen	NULL
cells	NULL
.	NULL

(	NULL
b	NULL
and	NULL
f	NULL
)	NULL
PBL	NULL
s.	NULL
(	NULL
c	NULL
and	NULL
g	NULL
)	NULL
Lymph	NULL
node	NULL
cells	NULL
.	NULL

(	NULL
d	NULL
and	NULL
/	NULL
)	NULL
Bone	NULL
marrow	NULL
cells	NULL
.	NULL

1	NULL
10	NULL
100	NULL
Thy	NULL
1.2	NULL
and	NULL
differentiation	NULL
(	NULL
42	NULL
,	NULL
43	NULL
)	NULL
.	NULL

In	NULL
a	NULL
similar	NULL
context	NULL
,	NULL
reports	NULL
that	NULL
several	NULL
transformed	NULL
cells	NULL
of	NULL
various	NULL
origins	NULL
were	NULL
accompanied	NULL
with	NULL
chromosomal	NULL
deletions	NULL
in	NULL
the	NULL
IFN	NULL
(	NULL
IFN-a1	NULL
and	NULL
IFN-	NULL
$	NULL
)	NULL
gene	NULL
loci	NULL
are	NULL
intriguing	NULL
as	NULL
to	NULL
the	NULL
role	NULL
of	NULL
IFNs	NULL
in	NULL
controlling	NULL
aberrant	NULL
cell	NULL
growth	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
previously	NULL
that	NULL
expression	NULL
of	NULL
the	NULL
IRF-1	NULL
gene	NULL
is	NULL
strongly	NULL
induced	NULL
not	NULL
only	NULL
by	NULL
viruses	NULL
but	NULL
also	NULL
by	NULL
IFNs	NULL
(	NULL
18	NULL
,	NULL
20	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
an	NULL
intriguing	NULL
issue	NULL
has	NULL
been	NULL
raised	NULL
concerning	NULL
the	NULL
role	NULL
of	NULL
IRF-1	NULL
in	NULL
IFN-induced	NULL
cellular	NULL
events	NULL
,	NULL
in	NULL
particular	NULL
for	NULL
inhibition	NULL
of	NULL
cell	NULL
growth	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
created	NULL
the	NULL
experimental	NULL
condition	NULL
in	NULL
which	NULL
the	NULL
human	NULL
IRF-1	NULL
gene	NULL
is	NULL
constitutively	NULL
expressed	NULL
at	NULL
high	NULL
levels	NULL
by	NULL
the	NULL
human	NULL
E	NULL
,	NULL
,	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

The	NULL
IRF-1	NULL
transgene	NULL
was	NULL
expressed	NULL
in	NULL
a	NULL
lymphoid	NULL
tissue-specific	NULL
manner	NULL
and	NULL
specific	NULL
depletion	NULL
of	NULL
the	NULL
B-cell	NULL
population	NULL
was	NULL
observed	NULL
in	NULL
such	NULL
transgenic	NULL
mice	NULL
.	NULL

Essentially	NULL
the	NULL
same	NULL
observation	NULL
was	NULL
made	NULL
with	NULL
another	NULL
line	NULL
of	NULL
transgenic	NULL
mouse	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
B-cell	NULL
depletion	NULL
is	NULL
primarily	NULL
caused	NULL
by	NULL
the	NULL
IRF-1	NULL
encoded	NULL
by	NULL
the	NULL
transgene	NULL
.	NULL

At	NULL
present	NULL
,	NULL
it	NULL
is	NULL
not	NULL
clear	NULL
by	NULL
which	NULL
mechanism	NULL
IRF-1	NULL
causes	NULL
B-cell	NULL
depletion	NULL
.	NULL

Although	NULL
the	NULL
transgene	NULL
is	NULL
also	NULL
expressed	NULL
in	NULL
the	NULL
thymus	NULL
,	NULL
no	NULL
significant	NULL
alternations	NULL
in	NULL
T-cell	NULL
population	NULL
and	NULL
function	NULL
were	NULL
observed	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
thymic	NULL
T	NULL
cells	NULL
do	NULL
not	NULL
express	NULL
the	NULL
IRF-1	NULL
sufficient	NULL
enough	NULL
to	NULL
perturb	NULL
their	NULL
growth	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
IRF-1	NULL
protein	NULL
might	NULL
exert	NULL
its	NULL
function	NULL
for	NULL
negative	NULL
cell	NULL
growth	NULL
through	NULL
regulating	NULL
the	NULL
expression	NULL
of	NULL
cellular	NULL
genes	NULL
,	NULL
such	NULL
as	NULL
IFN-	NULL
and	NULL
-a	NULL
genes	NULL
whose	NULL
expression	NULL
levels	NULL
may	NULL
depend	NULL
on	NULL
cell	NULL
types	NULL
.	NULL

So	NULL
far	NULL
,	NULL
we	NULL
have	NULL
been	NULL
unable	NULL
to	NULL
detect	NULL
any	NULL
IFN	NULL
or	NULL
IFN	NULL
mRNA	NULL
induction	NULL
in	NULL
lymphoid	NULL
tissues	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
we	NULL
have	NULL
provided	NULL
evidence	NULL
that	NULL
production	NULL
of	NULL
IRF-1	NULL
per	NULL
se	NULL
is	NULL
insufficient	NULL
for	NULL
IFN	NULL
gene	NULL
induction	NULL
in	NULL
differentiated	NULL
cells	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Although	NULL
,	NULL
we	NULL
can	NULL
not	NULL
strictly	NULL
rule	NULL
out	NULL
a	NULL
very	NULL
low	NULL
level	NULL
induction	NULL
of	NULL
IFN	NULL
genes	NULL
,	NULL
it	NULL
is	NULL
more	NULL
likely	NULL
that	NULL
IRF-1	NULL
affects	NULL
cell	NULL
growth	NULL
directly	NULL
rather	NULL
than	NULL
by	NULL
inducing	NULL
expression	NULL
of	NULL
IFNs	NULL
.	NULL

Whatever	NULL
the	NULL
mechanisms	NULL
,	NULL
this	NULL
may	NULL
be	NULL
a	NULL
unique	NULL
observation	NULL
that	NULL
cells	NULL
of	NULL
mice	NULL
expressing	NULL
the	NULL
transgene	NULL
for	NULL
a	NULL
cytokine-inducible	NULL
nuclear	NULL
factor	NULL
are	NULL
depleted	NULL
.	NULL

Table	NULL
1	NULL
.	NULL

Decreased	NULL
B-cell	NULL
precursor	NULL
frequency	NULL
and	NULL
CFU-IL-7	NULL
frequency	NULL
in	NULL
IRF-1	NULL
transgenic	NULL
mice	NULL
bone	NULL
marrow	NULL
cells	NULL
B-cell	NULL
precursor	NULL
frequency	NULL
CFU~-IL-7	NULL
,	NULL
IL-3	NULL
frequency	NULL
analysis*	NULL
analysis	NULL
?	NULL

IL-7	NULL
(	NULL
10	NULL
IL-3	NULL
(	NULL
200	NULL
Positive	NULL
well	NULL
Frequency	NULL
units/ml	NULL
)	NULL
units/ml	NULL
)	NULL
Littermate	NULL
mouse	NULL
17/96	NULL
1/513	NULL
12	NULL
(	NULL
+2	NULL
)	NULL
70	NULL
(	NULL
+10	NULL
)	NULL
IRF-1	NULL
transgenic	NULL
mouse	NULL
0/	NULL
%	NULL
6	NULL
<	NULL
1/9550	NULL
0	NULL
(	NULL
+0	NULL
)	NULL
%	NULL
9	NULL
(	NULL
+6	NULL
)	NULL
*Bone	NULL
marrow	NULL
cells	NULL
(	NULL
10°	NULL
)	NULL
were	NULL
overlaid	NULL
on	NULL
a	NULL
subconfluent	NULL
layer	NULL
of	NULL
PAG	NULL
cells	NULL
in	NULL
a	NULL
96-well	NULL
microculture	NULL
plate	NULL
and	NULL
12	NULL
days	NULL
after	NULL
the	NULL
culture	NULL
wells	NULL
containing	NULL
B220-positive	NULL
cells	NULL
were	NULL
scored	NULL
.	NULL

*Number	NULL
of	NULL
CFUs	NULL
(	NULL
+SD	NULL
)	NULL
obtained	NULL
per	NULL
2	NULL
x	NULL
10°	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

536	NULL
Immunology	NULL
:	NULL
Yamada	NULL
et	NULL
al	NULL
.	NULL

Recently	NULL
,	NULL
several	NULL
groups	NULL
showed	NULL
the	NULL
significant	NULL
roles	NULL
of	NULL
IL-7	NULL
as	NULL
well	NULL
as	NULL
bone	NULL
marrow-derived	NULL
stromal	NULL
cell	NULL
lines	NULL
in	NULL
their	NULL
functions	NULL
of	NULL
supporting	NULL
B-cell	NULL
development	NULL
(	NULL
34	NULL
,	NULL
38-40	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Nishikawa	NULL
and	NULL
colleagues	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
proposed	NULL
that	NULL
the	NULL
B-cell	NULL
differentiation	NULL
pathways	NULL
in	NULL
bone	NULL
marrow	NULL
cells	NULL
can	NULL
be	NULL
divided	NULL
into	NULL
three	NULL
stages	NULL
by	NULL
utilizing	NULL
recombinant	NULL
IL-7	NULL
and	NULL
bone	NULL
marrow-derived	NULL
stromal	NULL
cell	NULL
lines	NULL
.	NULL

They	NULL
are	NULL
(	NULL
?	NULL
)	NULL

the	NULL
pro-B-cell	NULL
stage	NULL
,	NULL
which	NULL
is	NULL
independent	NULL
of	NULL
the	NULL
cytokine	NULL
IL-7	NULL
(	NULL
41	NULL
)	NULL
,	NULL
and	NULL
(	NULL
i	NULL
?	NULL
)	NULL

the	NULL
early	NULL
pre-B-cell	NULL
stage	NULL
requiring	NULL
both	NULL
IL-7	NULL
and	NULL
stromal	NULL
cells	NULL
as	NULL
a	NULL
necessary	NULL
environment	NULL
,	NULL
and	NULL
(	NULL
/i	NULL
?	NULL
)	NULL

the	NULL
mature	NULL
(	NULL
late	NULL
)	NULL
early	NULL
pre-B-cell	NULL
stage	NULL
in	NULL
which	NULL
the	NULL
cells	NULL
can	NULL
proliferate	NULL
in	NULL
response	NULL
to	NULL
IL-7	NULL
alone	NULL
.	NULL

In	NULL
the	NULL
present	NULL
studies	NULL
,	NULL
the	NULL
frequency	NULL
of	NULL
generating	NULL
pre-B	NULL
cells	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
during	NULL
or	NULL
after	NULL
stage	NULL
if	NULL
?	NULL
)	NULL

of	NULL
transgenic	NULL
mice	NULL
was	NULL
significantly	NULL
low	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
B-cell	NULL
growth	NULL
is	NULL
affected	NULL
as	NULL
soon	NULL
as	NULL
the	NULL
E	NULL
,	NULL
,	NULL
starts	NULL
affecting	NULL
expression	NULL
of	NULL
the	NULL
transgene	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
murine	NULL
IL-7	NULL
receptor	NULL
(	NULL
IL-7R	NULL
)	NULL
is	NULL
expressed	NULL
on	NULL
pre-B	NULL
cells	NULL
but	NULL
not	NULL
on	NULL
mature	NULL
B	NULL
cells	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
murine	NULL
IL-7R	NULL
gene	NULL
contains	NULL
IRF-1	NULL
sites	NULL
within	NULL
its	NULL
promoter	NULL
region	NULL
(	NULL
Immunex	NULL
,	NULL
S.	NULL
F.	NULL
Ziegler	NULL
,	NULL
personal	NULL
communication	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
overexpression	NULL
of	NULL
IRF-1	NULL
might	NULL
affect	NULL
the	NULL
expression	NULL
of	NULL
murine	NULL
IL-7R	NULL
.	NULL

Recent	NULL
studies	NULL
indicate	NULL
that	NULL
IRF-2	NULL
,	NULL
a	NULL
factor	NULL
structurally	NULL
related	NULL
to	NULL
IRF-1	NULL
,	NULL
antagonizes	NULL
the	NULL
IRF-1	NULL
effect	NULL
by	NULL
competing	NULL
for	NULL
the	NULL
same	NULL
cis	NULL
elements	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

In	NULL
view	NULL
of	NULL
our	NULL
findings	NULL
with	NULL
IRF-1	NULL
transgenic	NULL
mice	NULL
,	NULL
it	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
examine	NULL
whether	NULL
B-cell	NULL
depletion	NULL
can	NULL
be	NULL
reversed	NULL
by	NULL
expressing	NULL
IRF-2	NULL
at	NULL
high	NULL
levels	NULL
.	NULL

Up	NULL
to	NULL
now	NULL
,	NULL
several	NULL
model	NULL
mice	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
have	NULL
various	NULL
immune	NULL
abnormalities	NULL
in	NULL
function	NULL
and/or	NULL
cell	NULL
composition	NULL
in	NULL
their	NULL
immune	NULL
systems	NULL
.	NULL

Studies	NULL
with	NULL
these	NULL
mice	NULL
have	NULL
greatly	NULL
contributed	NULL
to	NULL
understanding	NULL
the	NULL
functions	NULL
of	NULL
the	NULL
specific	NULL
subset	NULL
of	NULL
immune	NULL
cells	NULL
.	NULL

Similar	NULL
applications	NULL
with	NULL
these	NULL
IRF-1	NULL
transgenic	NULL
mice	NULL
might	NULL
provide	NULL
a	NULL
means	NULL
of	NULL
studying	NULL
various	NULL
immunological	NULL
problems	NULL
.	NULL

We	NULL
thank	NULL
Drs	NULL
.	NULL

K.	NULL
Willison	NULL
,	NULL
E.	NULL
L.	NULL
Barsoumian	NULL
,	NULL
S.	NULL
F.	NULL
Ziegler	NULL
,	NULL
L.	NULL
Park	NULL
,	NULL
T.	NULL
Matsuda	NULL
,	NULL
S.	NULL
Hayashi	NULL
,	NULL
and	NULL
S.	NULL
Ono	NULL
for	NULL
their	NULL
invaluable	NULL
advice	NULL
and	NULL
information	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Ms.	NULL
Y.	NULL
Maeda	NULL
for	NULL
her	NULL
excellent	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
a	NULL
Grant-in-Aid	NULL
for	NULL
Special	NULL
Project	NULL
Research	NULL
,	NULL
Cancer	NULL
Bioscience	NULL
and	NULL
a	NULL
Grant-in-Aid	NULL
for	NULL
Cancer	NULL
Research	NULL
from	NULL
the	NULL
Ministry	NULL
of	NULL
Education	NULL
,	NULL
Science	NULL
and	NULL
Culture	NULL
of	NULL
Japan	NULL
and	NULL
the	NULL
Nissan	NULL
Science	NULL
Foundation	NULL
,	NULL
respectively	NULL
.	NULL

1	NULL
.	NULL

Sporn	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

&	NULL
Roberts	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Peptide	NULL
Growth	NULL
Factors	NULL
and	NULL
Their	NULL
Receptors	NULL
I	NULL
(	NULL
Springer	NULL
,	NULL
New	NULL
York	NULL
)	NULL
.	NULL

2	NULL
.	NULL

Paul	NULL
,	NULL
W.	NULL
E.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
57	NULL
,	NULL
521-524	NULL
.	NULL

3	NULL
.	NULL

Lengyel	NULL
,	NULL
P.	NULL
;	NULL
(	NULL
1982	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

51	NULL
,	NULL
251-282	NULL
.	NULL

4	NULL
.	NULL

De	NULL
Maeyer	NULL
,	NULL
E.	NULL
&	NULL
Demaeyer-Guignard	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Interferons	NULL
and	NULL
Other	NULL
Regulatory	NULL
Cytokines	NULL
(	NULL
Wiley	NULL
,	NULL
New	NULL
York	NULL
)	NULL
.	NULL

5	NULL
.	NULL

Vilcek	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
in	NULL
Handbook	NULL
Experimental	NULL
Pharmacology	NULL
,	NULL
eds	NULL
.	NULL

Sporn	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

&	NULL
Roberts	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

(	NULL
Springer	NULL
,	NULL
New	NULL
York	NULL
)	NULL
Vol	NULL
.	NULL

95	NULL
II	NULL
,	NULL
pp	NULL
.	NULL

3-38	NULL
.	NULL

6	NULL
.	NULL

Borden	NULL
,	NULL
E.	NULL
C.	NULL
,	NULL
Hogan	NULL
,	NULL
T.	NULL
F.	NULL
&	NULL
Voelkel	NULL
,	NULL
J.	NULL
G.	NULL
(	NULL
1982	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

42	NULL
,	NULL
4948-4953	NULL
.	NULL

7	NULL
.	NULL

Broxmeyer	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
Lu	NULL
,	NULL
L.	NULL
,	NULL
Platzer	NULL
,	NULL
E.	NULL
,	NULL
Feit	NULL
,	NULL
C.	NULL
,	NULL
Juliano	NULL
,	NULL
L.	NULL
&	NULL
Rubin	NULL
,	NULL
B.	NULL
Y	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

131	NULL
,	NULL
1300-1305	NULL
.	NULL

8	NULL
.	NULL

Clemens	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

&	NULL
McNurlan	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

226	NULL
,	NULL
345-360	NULL
.	NULL

9	NULL
.	NULL

Moore	NULL
,	NULL
R.	NULL
N.	NULL
,	NULL
Larsen	NULL
,	NULL
H.	NULL
S.	NULL
,	NULL
Horohov	NULL
,	NULL
D.	NULL
W.	NULL
&	NULL
Rouse	NULL
,	NULL
B.	NULL
T.	NULL
(	NULL
1984	NULL
)	NULL
Science	NULL
223	NULL
,	NULL
178-181	NULL
.	NULL

10	NULL
.	NULL

Resnitzky	NULL
,	NULL
D.	NULL
,	NULL
Yarden	NULL
,	NULL
A.	NULL
,	NULL
Zipori	NULL
,	NULL
D.	NULL
&	NULL
Kimchi	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
,	NULL
31-40	NULL
.	NULL

11	NULL
.	NULL

Diaz	NULL
,	NULL
M.	NULL
O.	NULL
,	NULL
Ziemin	NULL
,	NULL
S.	NULL
,	NULL
Le	NULL
Beau	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
Pitha	NULL
,	NULL
P.	NULL
,	NULL
Smith	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
Chilcote	NULL
,	NULL
R.	NULL
R.	NULL
&	NULL
Rowley	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
,	NULL
5259-5263	NULL
.	NULL

12	NULL
.	NULL

Miyakoshi	NULL
,	NULL
J.	NULL
,	NULL
Dobler	NULL
,	NULL
K.	NULL
,	NULL
Allalunis-Turner	NULL
,	NULL
J.	NULL
,	NULL
McKean	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Petruk	NULL
,	NULL
K.	NULL
,	NULL
Allen	NULL
,	NULL
P.	NULL
B.	NULL
R.	NULL
,	NULL
Aronyk	NULL
,	NULL
K.	NULL
N.	NULL
,	NULL
Weir	NULL
,	NULL
B.	NULL
,	NULL
13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
(	NULL
1991	NULL
)	NULL
Huyser-Wierenga	NULL
,	NULL
D.	NULL
,	NULL
Fulton	NULL
,	NULL
D.	NULL
,	NULL
Urtasun	NULL
,	NULL
R.	NULL
C.	NULL
&	NULL
Day	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
III	NULL
(	NULL
1990	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

50	NULL
,	NULL
278-283	NULL
.	NULL

Sporn	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

&	NULL
Roberts	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
313	NULL
,	NULL
747-751	NULL
.	NULL

Fujita	NULL
,	NULL
T.	NULL
,	NULL
Shibuya	NULL
,	NULL
H.	NULL
,	NULL
Hotta	NULL
,	NULL
H.	NULL
,	NULL
Yamanishi	NULL
,	NULL
K.	NULL
&	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
49	NULL
,	NULL
357-367	NULL
.	NULL

Fujita	NULL
,	NULL
T.	NULL
,	NULL
Sakakibara	NULL
,	NULL
J.	NULL
,	NULL
Sudo	NULL
,	NULL
Y.	NULL
,	NULL
Miyamoto	NULL
,	NULL
M.	NULL
,	NULL
Kimura	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1988	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

7	NULL
,	NULL
3397-3405	NULL
.	NULL

Miyamoto	NULL
,	NULL
M.	NULL
,	NULL
Fujita	NULL
,	NULL
T.	NULL
,	NULL
Kimura	NULL
,	NULL
Y.	NULL
,	NULL
Maruyama	NULL
,	NULL
M.	NULL
,	NULL
Harada	NULL
,	NULL
H.	NULL
,	NULL
Sudo	NULL
,	NULL
Y.	NULL
,	NULL
Miyata	NULL
,	NULL
T.	NULL
&	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
54	NULL
,	NULL
903-913	NULL
.	NULL

Fujita	NULL
,	NULL
T.	NULL
,	NULL
Kimura	NULL
,	NULL
Y.	NULL
,	NULL
Miyamoto	NULL
,	NULL
M.	NULL
,	NULL
Barsoumian	NULL
,	NULL
E.	NULL
L.	NULL
&	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
337	NULL
,	NULL
270-272	NULL
.	NULL

Harada	NULL
,	NULL
H.	NULL
,	NULL
Fujita	NULL
,	NULL
T.	NULL
,	NULL
Miyamoto	NULL
,	NULL
M.	NULL
,	NULL
Kimura	NULL
,	NULL
Y.	NULL
,	NULL
Maruyama	NULL
,	NULL
M.	NULL
,	NULL
Furia	NULL
,	NULL
A.	NULL
,	NULL
Miyata	NULL
,	NULL
T.	NULL
&	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
58	NULL
,	NULL
729-739	NULL
.	NULL

Harada	NULL
,	NULL
H.	NULL
,	NULL
Willison	NULL
,	NULL
K.	NULL
,	NULL
Sakakibara	NULL
,	NULL
J.	NULL
,	NULL
Miyamoto	NULL
,	NULL
M.	NULL
,	NULL
Fujita	NULL
,	NULL
T.	NULL
&	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1990	NULL
)	NULL
Cell	NULL
63	NULL
,	NULL
303-312	NULL
.	NULL

Fujita	NULL
,	NULL
T.	NULL
,	NULL
Reis	NULL
,	NULL
L.	NULL
F.	NULL
L.	NULL
,	NULL
Watanave	NULL
,	NULL
N.	NULL
,	NULL
Kimura	NULL
,	NULL
Y.	NULL
,	NULL
Taniguchi	NULL
,	NULL
T.	NULL
&	NULL
Vilcek	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
9936-9940	NULL
.	NULL

Friedman	NULL
,	NULL
R.	NULL
L.	NULL
&	NULL
Stark	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1985	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
314	NULL
,	NULL
637-639	NULL
.	NULL

Revel	NULL
,	NULL
M.	NULL
&	NULL
Chebath	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

11	NULL
,	NULL
166-170	NULL
.	NULL

Berghe	NULL
,	NULL
V.	NULL
D.	NULL
,	NULL
Cassiman	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
David	NULL
,	NULL
G.	NULL
,	NULL
Fryns	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Michaux	NULL
,	NULL
J.	NULL
L.	NULL
&	NULL
Sokal	NULL
,	NULL
G.	NULL
(	NULL
1974	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
252	NULL
,	NULL
437-438	NULL
.	NULL

Hayday	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Gillies	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
Saito	NULL
,	NULL
H.	NULL
,	NULL
Wood	NULL
,	NULL
C.	NULL
,	NULL
Wiman	NULL
,	NULL
K.	NULL
,	NULL
Hayward	NULL
,	NULL
W.	NULL
S.	NULL
&	NULL
Tonegawa	NULL
,	NULL
S.	NULL
(	NULL
1984	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
307	NULL
,	NULL
334-340	NULL
.	NULL

Yamamura	NULL
,	NULL
K.	NULL
,	NULL
Kikutani	NULL
,	NULL
H.	NULL
,	NULL
Takahashi	NULL
,	NULL
N.	NULL
,	NULL
Taga	NULL
,	NULL
T.	NULL
,	NULL
Akira	NULL
,	NULL
S.	NULL
,	NULL
Kawai	NULL
,	NULL
K.	NULL
,	NULL
Fukuchi	NULL
,	NULL
K.	NULL
,	NULL
Kumahara	NULL
,	NULL
Y.	NULL
,	NULL
Honjo	NULL
,	NULL
T.	NULL
&	NULL
Kishimoto	NULL
,	NULL
T.	NULL
(	NULL
1984	NULL
)	NULL
J.	NULL
Biochem	NULL
.	NULL

(	NULL
Tokyo	NULL
)	NULL
96	NULL
,	NULL
357-363	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.	NULL
F.	NULL
&	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
in	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
,	NULL
ed	NULL
.	NULL

Nolan	NULL
,	NULL
C.	NULL
(	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Lab	NULL
.	NULL

,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
2nd	NULL
Ed	NULL
.	NULL

Maruyama	NULL
,	NULL
M.	NULL
,	NULL
Fujita	NULL
,	NULL
T.	NULL
&	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17	NULL
,	NULL
3292	NULL
.	NULL

Coffman	NULL
,	NULL
R.	NULL
L.	NULL
(	NULL
1982	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

69	NULL
,	NULL
5-23	NULL
.	NULL

Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

&	NULL
Herzenberg	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

47	NULL
,	NULL
63-90	NULL
.	NULL

Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

&	NULL
Seaman	NULL
,	NULL
W.	NULL
E.	NULL
(	NULL
1982	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

68	NULL
,	NULL
197-218	NULL
.	NULL

Dialynas	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
Wilde	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Marrack	NULL
,	NULL
P.	NULL
,	NULL
Pierres	NULL
,	NULL
A.	NULL
,	NULL
Wall	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Havran	NULL
,	NULL
W.	NULL
,	NULL
Otten	NULL
,	NULL
G.	NULL
,	NULL
Loken	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Pierres	NULL
,	NULL
M.	NULL
,	NULL
Kappler	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Fitch	NULL
,	NULL
F.	NULL
W.	NULL
(	NULL
1983	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

74	NULL
,	NULL
29-56	NULL
.	NULL

Hardy	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
Kishimoto	NULL
,	NULL
T.	NULL
&	NULL
Hayakawa	NULL
,	NULL
K.	NULL
(	NULL
1987	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

17	NULL
,	NULL
1769-1774	NULL
.	NULL

Jerne	NULL
,	NULL
N.	NULL
K.	NULL
&	NULL
Nordin	NULL
,	NULL
A	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1963	NULL
)	NULL
Science	NULL
140	NULL
,	NULL
405-406	NULL
.	NULL

Nishikawa	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Ogawa	NULL
,	NULL
M.	NULL
,	NULL
Nishikawa	NULL
,	NULL
S.	NULL
,	NULL
Kunisada	NULL
,	NULL
T.	NULL
&	NULL
Kodama	NULL
,	NULL
H.	NULL
(	NULL
1988	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

18	NULL
,	NULL
1767-1771	NULL
.	NULL

Sudo	NULL
,	NULL
T.	NULL
,	NULL
Ito	NULL
,	NULL
M.	NULL
,	NULL
Ogawa	NULL
,	NULL
Y.	NULL
,	NULL
Iizuka	NULL
,	NULL
M.	NULL
,	NULL
Kodama	NULL
,	NULL
H.	NULL
,	NULL
Kunisada	NULL
,	NULL
T.	NULL
,	NULL
Hayashi	NULL
,	NULL
S.	NULL
,	NULL
Ogawa	NULL
,	NULL
M.	NULL
,	NULL
Sakai	NULL
,	NULL
K.	NULL
,	NULL
Nishikawa	NULL
,	NULL
S.	NULL
&	NULL
Nishikawa	NULL
,	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

170	NULL
,	NULL
333-338	NULL
.	NULL

Osmond	NULL
,	NULL
D.	NULL
G.	NULL
(	NULL
1986	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

93	NULL
,	NULL
103-124	NULL
.	NULL

Kincade	NULL
,	NULL
P.	NULL
W.	NULL
(	NULL
1988	NULL
)	NULL
Adv	NULL
.	NULL

Immunol	NULL
.	NULL

41	NULL
,	NULL
181-267	NULL
.	NULL

Hunt	NULL
,	NULL
P.	NULL
,	NULL
Robertson	NULL
,	NULL
D.	NULL
,	NULL
Weiss	NULL
,	NULL
D.	NULL
,	NULL
Rennick	NULL
,	NULL
D.	NULL
,	NULL
Lee	NULL
,	NULL
F.	NULL
&	NULL
Witte	NULL
,	NULL
O.	NULL
N.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
48	NULL
,	NULL
997-1007	NULL
.	NULL

Landreth	NULL
,	NULL
K.	NULL
&	NULL
Dorshkind	NULL
,	NULL
K.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

140	NULL
,	NULL
845-852	NULL
.	NULL

Whitlock	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Tidmarsh	NULL
,	NULL
G.	NULL
F.	NULL
,	NULL
Muller-Sicburg	NULL
,	NULL
C.	NULL
&	NULL
Weissman	NULL
,	NULL
I.	NULL
L.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
48	NULL
,	NULL
1009-1021	NULL
.	NULL

Lee	NULL
,	NULL
G.	NULL
,	NULL
Namen	NULL
,	NULL
A.	NULL
,	NULL
Gillis	NULL
,	NULL
S.	NULL
,	NULL
Ellingsworth	NULL
,	NULL
L.	NULL
R.	NULL
&	NULL
Kincade	NULL
,	NULL
P.	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

142	NULL
,	NULL
3875-3883	NULL
.	NULL

Shah	NULL
,	NULL
G.	NULL
,	NULL
Dexter	NULL
,	NULL
T.	NULL
M.	NULL
&	NULL
Lanotte	NULL
,	NULL
M.	NULL
(	NULL
1983	NULL
)	NULL
Br	NULL
.	NULL

J.	NULL
Haematol	NULL
.	NULL

54	NULL
,	NULL
365-372	NULL
.	NULL

Zoumbos	NULL
,	NULL
N.	NULL
C.	NULL
,	NULL
Gascon	NULL
,	NULL
P.	NULL
,	NULL
Djeu	NULL
,	NULL
J.	NULL
Y	NULL
.	NULL

&	NULL
Young	NULL
,	NULL
N.	NULL
S.	NULL
(	NULL
1985	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82	NULL
,	NULL
188-192	NULL
.	NULL

Henny	NULL
,	NULL
C.	NULL
E.	NULL
(	NULL
1989	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
10	NULL
,	NULL
170-173	NULL
.	NULL

Park	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
Friend	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Schmierer	NULL
,	NULL
A.	NULL
N.	NULL
,	NULL
Dower	NULL
,	NULL
S.	NULL
K.	NULL
&	NULL
Namen	NULL
,	NULL
A.	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

171	NULL
,	NULL
1073-1089	NULL
.	NULL

